NLTX logo

Neoleukin Therapeutics (NLTX) Net Income

NLTX Annual Net Income

-$57.56 M
+$3.13 M+5.17%

31 December 2022

1-Year Change

+5.17%
NLTX annual net profit is up +5.17% year-on-year

3-Year Change

+17.12%
NLTX annual net profit is up +17.12% over the past 3 years

All-time High

-$12.14 M

Annual Net Income Formula

Revenue − COGS − Operating Expenses − Interest − Taxes − Other Expenses
Annual EPS-$20.80
NLTX annual earnings per share is -$20.80

NLTX Net Income Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

NLTX Quarterly Net Income

-$4.53 M
-$2.44 M-117.07%

30 September 2023

1-Year Change

+65.38%
NLTX quarterly net profit is up +65.38% year-on-year

3-Year Change

-101.24%
NLTX quarterly net profit is down -101.24% over the past 3 years

All-time High

$2.92 M
NLTX quarterly net profit is currently -255.11% below its historical high of $2.92 million
Quarterly EPS-$1.64
NLTX quarterly earnings per share is -$1.64

NLTX Quarterly Net Income Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

NLTX TTM Net Income

-$34.26 M
+$8.55 M+19.96%

30 September 2023

1-Year Change

+42.2%
NLTX TTM net profit is up +42.2% year-on-year

3-Year Change

-19.21%
NLTX TTM net profit is down -19.21% over the past 3 years

All-time High

-$2.56 M
TTM EPS-$12.48
NLTX TTM earnings per share is -$12.48

NLTX TTM Net Income Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

NLTX Net Income Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+5.2%+65.4%+42.2%
3 y3 years+17.1%-101.2%-19.2%
5 y5 years-14.7%+69.8%+50.7%

NLTX Net Income High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year
5 y5-year
alltimeall time+374.2%-255.1%+1239.1%

Neoleukin Therapeutics Net Income History

DateAnnualQuarterlyTTM
Sept 2023
-
-$4.53 M(+117.1%)
-$34.26 M(-20.0%)
June 2023
-
-$2.08 M(-85.3%)
-$42.81 M(-24.1%)
Mar 2023
-
-$14.20 M(+5.6%)
-$56.41 M(-2.0%)
Dec 2022
-$57.56 M(-5.2%)
-$13.45 M(+2.9%)
-$57.56 M(-2.9%)
Sept 2022
-
-$13.07 M(-16.7%)
-$59.28 M(-3.9%)
June 2022
-
-$15.69 M(+2.2%)
-$61.65 M(+0.9%)
Mar 2022
-
-$15.35 M(+1.2%)
-$61.09 M(+0.7%)
Dec 2021
-$60.69 M(+82.4%)
-$15.17 M(-1.8%)
-$60.69 M(+4.3%)
Sept 2021
-
-$15.45 M(+2.1%)
-$58.16 M(+29.3%)
June 2021
-
-$15.13 M(+1.2%)
-$44.97 M(+13.6%)
Mar 2021
-
-$14.95 M(+18.3%)
-$39.59 M(+19.0%)
Dec 2020
-$33.28 M(-52.1%)
-$12.64 M(+462.0%)
-$33.28 M(+15.8%)
Sept 2020
-
-$2.25 M(-76.9%)
-$28.74 M(-66.4%)
June 2020
-
-$9.75 M(+12.8%)
-$85.62 M(+12.8%)
Mar 2020
-
-$8.64 M(+6.7%)
-$75.88 M(+9.3%)
Dec 2019
-$69.44 M(+119.9%)
-$8.10 M(-86.3%)
-$69.44 M(+4.9%)
Sept 2019
-
-$59.13 M(>+9900.0%)
-$66.23 M(+199.8%)
June 2019
-
-$1000.00(-100.0%)
-$22.09 M(+15.2%)
Mar 2019
-
-$2.21 M(-54.8%)
-$19.17 M(-39.3%)
Dec 2018
-$31.59 M
-$4.89 M(-67.4%)
-$31.59 M(-26.5%)
Sept 2018
-
-$14.99 M(-613.8%)
-$42.97 M(+7.9%)
June 2018
-
$2.92 M(-120.0%)
-$39.81 M(-29.5%)
DateAnnualQuarterlyTTM
Mar 2018
-
-$14.62 M(-10.1%)
-$56.49 M(+12.6%)
Dec 2017
-$50.18 M(+35.6%)
-$16.27 M(+37.5%)
-$50.18 M(+11.1%)
Sept 2017
-
-$11.83 M(-14.0%)
-$45.16 M(+8.9%)
June 2017
-
-$13.77 M(+65.5%)
-$41.47 M(+7.4%)
Mar 2017
-
-$8.32 M(-26.0%)
-$38.61 M(+4.3%)
Dec 2016
-$37.00 M(+69.3%)
-$11.24 M(+38.0%)
-$37.00 M(+17.8%)
Sept 2016
-
-$8.15 M(-25.3%)
-$31.42 M(+11.0%)
June 2016
-
-$10.90 M(+62.4%)
-$28.31 M(+27.8%)
Mar 2016
-
-$6.71 M(+18.5%)
-$22.16 M(+1.4%)
Dec 2015
-$21.86 M(-8.2%)
-$5.66 M(+12.5%)
-$21.86 M(-10.0%)
Sept 2015
-
-$5.04 M(+6.0%)
-$24.29 M(-4.9%)
June 2015
-
-$4.75 M(-25.9%)
-$25.54 M(-2.6%)
Mar 2015
-
-$6.41 M(-20.7%)
-$26.21 M(+10.0%)
Dec 2014
-$23.82 M(+59.4%)
-$8.09 M(+28.7%)
-$23.82 M(+13.4%)
Sept 2014
-
-$6.28 M(+15.9%)
-$21.01 M(+8.0%)
June 2014
-
-$5.42 M(+34.9%)
-$19.45 M(+18.5%)
Mar 2014
-
-$4.02 M(-23.8%)
-$16.40 M(+9.8%)
Dec 2013
-$14.94 M(+23.1%)
-$5.28 M(+11.9%)
-$14.94 M(+54.7%)
Sept 2013
-
-$4.72 M(+98.2%)
-$9.66 M(+95.5%)
June 2013
-
-$2.38 M(-6.9%)
-$4.94 M(+93.1%)
Mar 2013
-
-$2.56 M
-$2.56 M
Dec 2012
-$12.14 M
-
-

FAQ

  • What is Neoleukin Therapeutics annual net profit?
  • What is the all time high annual net income for Neoleukin Therapeutics?
  • What is Neoleukin Therapeutics annual net income year-on-year change?
  • What is Neoleukin Therapeutics quarterly net profit?
  • What is the all time high quarterly net income for Neoleukin Therapeutics?
  • What is Neoleukin Therapeutics quarterly net income year-on-year change?
  • What is Neoleukin Therapeutics TTM net profit?
  • What is the all time high TTM net income for Neoleukin Therapeutics?
  • What is Neoleukin Therapeutics TTM net income year-on-year change?

What is Neoleukin Therapeutics annual net profit?

The current annual net income of NLTX is -$57.56 M

What is the all time high annual net income for Neoleukin Therapeutics?

Neoleukin Therapeutics all-time high annual net profit is -$12.14 M

What is Neoleukin Therapeutics annual net income year-on-year change?

Over the past year, NLTX annual net profit has changed by +$3.13 M (+5.17%)

What is Neoleukin Therapeutics quarterly net profit?

The current quarterly net income of NLTX is -$4.53 M

What is the all time high quarterly net income for Neoleukin Therapeutics?

Neoleukin Therapeutics all-time high quarterly net profit is $2.92 M

What is Neoleukin Therapeutics quarterly net income year-on-year change?

Over the past year, NLTX quarterly net profit has changed by +$8.55 M (+65.38%)

What is Neoleukin Therapeutics TTM net profit?

The current TTM net income of NLTX is -$34.26 M

What is the all time high TTM net income for Neoleukin Therapeutics?

Neoleukin Therapeutics all-time high TTM net profit is -$2.56 M

What is Neoleukin Therapeutics TTM net income year-on-year change?

Over the past year, NLTX TTM net profit has changed by +$25.02 M (+42.20%)